Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment

Cancer Immunology Immunotherapy

Volumn 44, Issue 5, 1997, Pages 265-272

  Clark, Joseph I ^a,d   Alpaugh, R Katherine ^a   Von Mehren, Margaret ^a   Schultz, Josephine ^a   Gralow, Julie R ^b   Cheever, Martin A ^b   Ring, David B ^c   Weiner, Louis M ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Bispecific antibody; c erbB 2; CD16; Immunization

Indexed keywords

BISPECIFIC ANTIBODY; IDIOTYPIC ANTIBODY; IMMUNOGLOBULIN ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2 B 1; ONCOPROTEIN; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ANTIBODY PRODUCTION; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; HUMAN; HUMORAL IMMUNITY; ONCOGENE C ERB; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ADENOCARCINOMA; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; RECEPTOR, ERBB-2; RECEPTORS, IGG; VACCINATION;

EID: 0030796916     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050382     Document Type: Article

References (34)

1. Bhattacharya-Chatterjee M, Chatterjee SK, Vasile S, Seon BK, Köhler H (1988) Idiotype vaccines against human T cell leukemia. II. Generation and characterization of a monoclonal idiotype cascade (Ab1, Ab2, and Ab3). J Immunol 141:1398
2. Bhattacharya-Chatterjee M, Foon KA, Köhler H (1994) Idiotypic antibody immunotherapy of cancer. Cancer Immunol Immunother 38:75
3. Cheung NK, Burch L, Kushner BH, Munn DH (1991) Monoclonal antibody 3F8 can effect durable remissions in neuroblastoma patients refractory to chemotherapy: a phase II trial. Prog Clin Biol Res 366:395
4. DePalazzo IG, Gercel-Taylor C, Kitson J, Weiner LM (1990) Potentiation of tumor lysis by a bispecific antibody that binds to CA19-9 antigen and the Fcγ receptor expressed by human large granular lymphocytes. Cancer Res 50:7123
5. Dillman RO (1990) The human antimouse response. Antibody Immunoconjugates Radiopharm 3:1
6. 3) of importance for tumor response to therapy? Cancer Immunol Immunother 38:149
7. Fanger MW, Segal DM, Romet-Lemonne JL (1991) Bispecific antibodies and targeted cellular cytotoxicity. Immunol Today 12:51-54
8. Ferrini S, Prigione I, Miotti S, Ciccone E, Cantoni C, Chen Q, Colnaghi MI, Moretta L (1991) Bispecific monoclonal antibodies directed to CD16 and to a tumor-associated antigen induce target-cell lysis by resting NK cells and by a subset of NK clones. Int J Cancer 48:227
9. Fleit HD, Wright SD, Unkeless JC (1982) Human neutrophil Fcγ receptor distribution and structure. Proc Natl Acad Sci USA 79:3275-3279
10. Frankel AE, Ring DB, Tringale F, Hsieh-Ma ST (1985) Tissue distribution of breast cancer-associated antigens defined by monoclonal antibodies. J Biol Response Mod 4:273
11. Gosselin EJ, Wardwell K, Gosselin DR, Alter N, Fisher JL, Guyre PM (1992) Enhanced antigen presentation using human Fc gamma receptor (monocyte/macrophage)-specific immunogens. J Immunol 149:3477
12. Gralow J, Weiner L, Ring D, Clark J, Alpaugh K, Disis M, Cheever M (1995) HER-2/neu specific immunity can be induced by therapy with 2B1, a bispecific monoclonal antibody binding to HER-2/neu and CD16. Proc ASCO 14:546
13. Herlyn D, Wettendorff M, Schmoll E, Iliopoulos D, Schedel I, Dreikhausen U, Raab R, Ross AH, Jaksche H, Scriba M, Koprowski H (1987) Anti-idiotype immunization of cancer patients: modulation of the immune response. Proc Natl Acad Sci USA 84:8055
14. Hombach A, Wolfram J, Pohl C, Renner C, Sahin U, Shmits R, Wolf J, Kapp U, Diehl V, Pfreundschuh M (1993) A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo. Int J Cancer 55:830
15. Hsieh-Ma ST, Eaton AM, Shi T, Ring DB (1992) In vitro cytotoxic targeting by human mononuclear cells and bispecific antibody 2B1, recognizing c-erbB-2 protooncogene product and Fcγ receptor III. Cancer Res 52:6832
16. Jerne NK (1974) Towards a network theory of the immune system. Ann Immunol 125:373
17. Khayat D, Soubrane C, Andrieu JM, Visonneau S, Eme D, Tourani JM, Beldjord K, Weil M, Fernandez E, Jacquillat C (1990) Changes of soluble CD16 levels in serum of HIV-infected patients: correlation with clinical and biologic prognostic factors. J Infect Dis 161:430
18. Lanzavecchia A, Scheidegger D (1987) The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur J Immunol 17:105
19. Lowder JN, Meeker TC, Campbell M, Garcia CF, Gralow J, Miller RA, Warnke R, Levy R (1987) Studies on B lymphoid tumors treated with monoclonal anti-idiotype antibodies: correlation with clinical responses. Blood 69:199
20. Mittleman A, Chen ZJ, Yang H, Wong GY, Ferrone S (1992) Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci USA 89:466
21. Perez P, Hoffman RW, Shaw S, Bluestone JA, Segal D (1985) Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature 316:354
22. Qian JH, Titus JA, Andrew SM, Mezzanzanica D, Garrido MA, Wunderlich JR, Segal DM (1991) Human peripheral blood lymphocytes targeted with bispecific antibodies release cytokines that are essential for inhibiting tumor growth. J Immunol 146:3250
23. r 200,000 glycoprotein selectively associated with human breast cancer. Cancer Res 49:3070
24. Saleh MN, Khazaeli MB, Grizzle WE, Wheeler RH, Lawson S, Liu T, Russell C, Meredith R, Schlom J, LoBuglio AF (1993) A phase I clinical trial of murine monoclonal antibody D612 in patients with metastatic gastrointestinal cancer. Cancer Res 53:4555
25. Shi T, Eaton AM, Ring DB (1991) Selection of hybrid hybridomas by flow cytometry using a new combination of fluorescent vital stains. J Immunol Methods 141:165
26. Snider DP, Kaubisch A, Segal DM (1990) Enhanced antigen immunogenicity induced by bispecific antibodies. J Exp Med 171:1957
27. Staerz UD, Kanagawa O, Bevan MJ (1985) Hybrid antibodies can target sites for attack by T cells. Nature 314:628
28. Vadhan-Raj S, Cordon-Cardo C, Carswell E, Mintzer D, Dantis L, Duteau C, Templeton MA, Oettgen HF, Old LJ, Houghton AN (1988) Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. J Clin Oncol 6:1636
29. Van Dijk J, Tsuruo T, Segal DM, Bolhuis RLH, Colognola R, Griend RJ van de, Fleuren GJ, Warnaar SD (1989) Bispecific antibodies reactive with the multidrug-resistance-related glycoprotein and CD3 induce lysis of multidrug-resistant tumor cells. Int J Cancer 44:738
30. Weiner GJ, Hillstrom JR (1991) Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma. J Immunol 147:4035
31. Weiner LM, Holmes M, Adams GP, LaCreta F, Watts P, dePalazzo IG (1993) A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16. Cancer Res 53:94
32. Weiner LM, Ring D, Li W, Palazzo IE, Davey M, Rivera V, Alpaugh RK (1994) Phase 1 trial of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and CD16. Proc Am Soc Clin Oncol 13:300
33. Weiner LM, Clark JI, Davey M, Li WS, Garcia dePalazzo I, Ring DB, Alpaugh RK (1995) Phase I trial of 2B1, A bispecific monoclonal antibody targeting c-erbB-2 and FcγRIII. Cancer Res. 55:4586
34. Wettendorf M, Iliopoulos D, Tempero M, Kay D, DeFreitas E, Koprowski H, Herlyn D (1989) Idiotypic cascades in cancer patients treated with monoclonal antibody CO17-11A. Proc Natl Acad Sci USA 86:3787